Results 11 to 20 of about 8,174 (197)

Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan.
Shah S, Mafirakureva N, Trickey A, Hasnain A, Khan U, Khowaja S, Ashraf H, Baig-Ansari N, Hickman M, Vickerman P, Walker JG, Lim AG.   +11 more
europepmc   +2 more sources

High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam. [PDF]

J Viral Hepat
ABSTRACT People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low‐ and middle‐income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high‐risk population.
Laureillard D, Binh NT, Vinh VH, Hong TT, Quillet C, Thanh NTT, Vallo R, Quynh BTN, Moles JP, Oanh KTH, Huong DT, Rapoud D, Feelemyer J, Michel L, Vickerman P, Fraser H, Weiss L, Lemoine M, Lacombe K, Jarlais DD, Khue PM, Nagot N.   +21 more
europepmc   +2 more sources

Decentralised Hepatitis C Management: A Simplified, Integrated Model of Care in a Primary Health Centre in Pakistan, August 2022-June 2023. [PDF]

J Viral Hepat
ABSTRACT Pakistan has the world's highest hepatitis C virus (HCV) prevalence, yet access to HCV care remains limited. In collaboration with the Ministry of Health Sindh, Médecins Sans Frontières implemented a simplified, decentralised model for HCV screening and treatment at a government‐run primary health centre (PHC) in Baldia Town, Karachi, Pakistan.
Mazzilli S, Aslam MK, Ahmed M, Wailly Y, Miazek M, Ashraf S, Ravji A, de Glanville WA, Isaakidis P.   +8 more
europepmc   +2 more sources

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
ABSTRACT Direct‐acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype‐specific to pan‐genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines.
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +2 more sources

Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trialResearch in context

The Lancet Regional Health. Americas, 2023
Summary: Background: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients ...
Israel S. Maia, Aline Marcadenti, Viviane C. Veiga, Tamiris A. Miranda, Samara P.C. Gomes, Mariana B.S. Carollo, Karina L. Negrelli, Jackeline O. Gomes, Lucas Tramujas, Erlon O. Abreu-Silva, Glauco A. Westphal, Ruthy P. Fernandes, Jacques G.A. Horta, Deborah C. Oliveira, Uri A.P. Flato, Ricardo C.R. Paoliello, Camilo Fernandes, Cássio L. Zandonai, Juliana C. Coelho, Waldemar C. Barros, Juliana C. Lemos, Renata S. Bolan, Marcela M. Dutra, Otavio C.E. Gebara, Ana T.A. Lopes, Meton S. Alencar Filho, Jussara A. Arraes, Victor A. Hamamoto, Mauro E. Hernandes, Nicole A. Golin, Tiago M. Santos, Renato H.N. Santos, Lucas P. Damiani, Fernando G. Zampieri, João Gesto, Flávia R. Machado, Régis G. Rosa, Luciano C.P. Azevedo, Alvaro Avezum, Renato D. Lopes, Thiago M.L. Souza, Otávio Berwanger, Alexandre B. Cavalcanti   +42 more
doaj   +1 more source

SARS-CoV-2 Papain-like Protease Responsive ZnO/Daclatasvir-Loaded Chitosan/Gelatin Nanofibers as Smart Antimicrobial Medical Textiles: In Silico, In Vitro and Cell Studies

Pharmaceutics, 2023
A significant number of deaths are reported annually worldwide due to microbial and viral infections. The development of protective medical textiles for patients and healthcare professionals has attracted many researchers’ attention.
Mohamed Hamdi, Akram M. Elkashlan, Mohamed A. Hammad, Isra H. Ali   +3 more
doaj   +1 more source

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients [PDF]

International Journal of Medical Arts, 2021
Background: Chronic Hepatitis-C virus [HCV] infection is endemic in Egypt, with the highest prevalence worldwide. There are few studies on the effectiveness and safety of direct acting antivirals in treating geriatric patients with chronic HCV.
Mohamed G. Mohamed, Mohamed B. Bastawy, Mostafa A. Elhawary, Mohamed R. Rashed   +3 more
doaj   +1 more source

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]

Терапевтический архив, 2019
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk   +11 more
doaj   +1 more source

Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors

Viruses, 2022
Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental ...
Tamer Nasr, Ahmed M. Aboshanab, George Mpekoulis, Antonios Drakopoulos, Niki Vassilaki, Grigoris Zoidis, Khaled A. M. Abouzid, Wafaa Zaghary   +7 more
doaj   +1 more source

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources